Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals

Table 1 Evaluated scenarios for projections of the future burden of hepatitis C infection in Greece

Scenario	Year	SVR	Treatment coverage/yr	Fibrosis stage	Diagnosed patients/yr
Base case	2015-2016	90%-95%	~1000	≥ F3	4000
	2017-2019	95%	~2000	≥ F2	3200
	2020-2021	95%	~1300	≥ F2	2000
	2022-2023	95%	~1000	≥ F2	1400
	2024-2035	95%	~1000	≥ F2	1000
WHO Global Hepatitis Strategy	2015-2016	90%-95%	~1000	≥ F3	4000
	2017-2019	95%	~4700	≥ F2	4800
	2020-2021	95%	~6800	≥ F0	6820
	2022-2023	95%	~6800	≥ F0	6130
	2024-2035	95%	~7000	≥ F0	6130

SVR: Sustained virologic response rates; WHO: World Health Organization.